Literature DB >> 9327523

IL-12 as an adjuvant for cell-mediated immunity.

P Scott1, G Trinchieri.   

Abstract

Recent studies have shown that IL-12 initiates the development of cell-mediated immunity following infection with certain infectious agents. This attribute of IL-12 makes it a potentially effective adjuvant for vaccines. This review summarizes our findings in the Leishmania system, outlining the role of endogenous IL-12 in resistance to L. major and the use of exogenous IL-12 in a vaccine against L. major, and also describes other examples in which IL-12 has been shown to be effective as an adjuvant at inducing protective immunity. The potential use of IL-12 as an adjuvant in therapeutic vaccines is also discussed.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9327523     DOI： 10.1006/smim.1997.0084

Source DB:  PubMed          Journal:  Semin Immunol        ISSN： 1044-5323            Impact factor:   11.130


  18 in total

Review 1.  The role of gamma/delta T cells in immunity to infection and regulation of inflammation.

Authors:  H Kirk Ziegler
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

2.  In vivo efficacy of a chitosan/IL-12 adjuvant system for protein-based vaccines.

Authors:  Michael J Heffernan; David A Zaharoff; Jonathan K Fallon; Jeffrey Schlom; John W Greiner
Journal:  Biomaterials       Date:  2010-10-20       Impact factor: 12.479

Review 3.  Leishmaniasis: current status of vaccine development.

Authors:  E Handman
Journal:  Clin Microbiol Rev       Date:  2001-04       Impact factor: 26.132

4.  Vaccination against the intracellular pathogens Leishmania major and L. amazonensis by directing CD40 ligand to macrophages.

Authors:  G Chen; P A Darrah; D M Mosser
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

5.  Recombinant herpes simplex virus type 1 (HSV-1) codelivering interleukin-12p35 as a molecular adjuvant enhances the protective immune response against ocular HSV-1 challenge.

Authors:  Yanira Osorio; Homayon Ghiasi
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

6.  Murine gammaherpesvirus-68-induced interleukin-10 increases viral burden, but limits virus-induced splenomegaly and leukocytosis.

Authors:  J W Peacock; K L Bost
Journal:  Immunology       Date:  2001-09       Impact factor: 7.397

7.  Vervet monkeys vaccinated with killed Leishmania major parasites and interleukin-12 develop a type 1 immune response but are not protected against challenge infection.

Authors:  M M Gicheru; J O Olobo; C O Anjili; A S Orago; F Modabber; P Scott
Journal:  Infect Immun       Date:  2001-01       Impact factor: 3.441

8.  Interleukin-12 as a genetic adjuvant enhances hepatitis C virus NS3 DNA vaccine immunogenicity.

Authors:  Malihe Naderi; Atefeh Saeedi; Abdolvahab Moradi; Mishar Kleshadi; Mohammad Reza Zolfaghari; Ali Gorji; Amir Ghaemi
Journal:  Virol Sin       Date:  2013-05-25       Impact factor: 4.327

9.  DNA-based vaccines protect against zoonotic schistosomiasis in water buffalo.

Authors:  Akram A Da'dara; Yuesheng S Li; Tie Xiong; Jie Zhou; Gail M Williams; Donald P McManus; Zheng Feng; Xin L Yu; Darren J Gray; Donald A Harn
Journal:  Vaccine       Date:  2008-05-19       Impact factor: 3.641

10.  Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis.

Authors:  Rhea N Coler; Yasir A W Skeiky; Karen Bernards; Kay Greeson; Darrick Carter; Charisa D Cornellison; Farrokh Modabber; Antonio Campos-Neto; Steven G Reed
Journal:  Infect Immun       Date:  2002-08       Impact factor: 3.441
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.